Resolution of rhinocerebral zygomycosis associated with adjuvant administration of granulocyte-macrophage colony-stimulating factor

J B Garcia-Diaz; L Palau; G A Pankey

doi:10.1086/320767

Resolution of rhinocerebral zygomycosis associated with adjuvant administration of granulocyte-macrophage colony-stimulating factor

Clin Infect Dis. 2001 Jun 15;32(12):e145-50. doi: 10.1086/320767. Epub 2001 May 7.

Authors

J B Garcia-Diaz¹, L Palau, G A Pankey

Affiliation

¹ Department of Infectious Diseases, Ochsner Clinic and Alton Ochsner Medical Foundation, New Orleans, LA, USA.

PMID: 11360225
DOI: 10.1086/320767

Abstract

We successfully treated 3 consecutive patients who had nonneutropenic rhinocerebral zygomycosis, by use of subcutaneous granulocyte-macrophage colony-stimulating factor therapy combined with traditional surgical and medical treatment. All patients are currently free of disease. Granulocyte-macrophage colony-stimulating factor should be considered as adjuvant therapy for rhinocerebral zygomycosis; however, optimum dose and length of therapy are unknown.

Publication types

Case Reports

MeSH terms

Adjuvants, Pharmaceutic / administration & dosage
Adjuvants, Pharmaceutic / therapeutic use*
Aged
Amphotericin B / therapeutic use
Drug Combinations
Female
Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage
Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use*
Humans
Male
Middle Aged
Mucormycosis / drug therapy*
Mucormycosis / pathology
Mucormycosis / surgery
Phosphatidylcholines / therapeutic use
Phosphatidylglycerols / therapeutic use
Rhizopus / drug effects*
Rhizopus / isolation & purification
Treatment Outcome

Substances

Adjuvants, Pharmaceutic
Drug Combinations
Phosphatidylcholines
Phosphatidylglycerols
liposomal amphotericin B
Amphotericin B
Granulocyte-Macrophage Colony-Stimulating Factor